Sana Biotechnology

Eolo Pharma published first-in-human data in Nature Metabolism showing SANA, a first-in-class compound, safely activates creatine-dependent thermogenesis to increase energy expenditure rather than suppress appetite.

Sana Biotechnology will present at two major investor conferences in June 2025, including the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference.

SANA, a derivative of salicylate, demonstrated weight loss and improved insulin resistance in healthy, overweight, and obese volunteers during a phase 1 clinical trial with doses up to 800 mg.

• Tenvie Therapeutics, backed by Arch Venture Partners and others, debuts with $200 million to develop drugs targeting neurodegenerative diseases. • Sana Biotechnology's technology enables successful pancreatic islet cell transplant in a Type 1 diabetes patient without immunosuppression. • Jasper Therapeutics shares mixed Phase 1b/2a data on briquilimab for chronic spontaneous urticaria, leading to a stock decline. • Stoke Therapeutics finalizes plans for a Phase 3 trial of its experimental drug for Dravet syndrome, with data expected by 2027.

• Sana Biotechnology's HIP-modified islet cells demonstrated immune evasion and C-peptide production in a Type 1 Diabetes patient without immunosuppression. • The positive Phase 1 data supports the potential of Sana's hypoimmune (HIP) cell platform, leading to increased price targets from analysts. • A single patient in the trial showed stable C-peptide levels 4 weeks post-injection, indicating the HIP cells' survival and function without triggering an immune response. • Sana Biotechnology's progress in Type 1 Diabetes treatment has been recognized, potentially setting a more favorable stage for its stock performance.

Sana Biotechnology's UP421 demonstrated survival and function of transplanted pancreatic beta cells in a type 1 diabetes patient without immunosuppression.

• The FDA granted breakthrough therapy designation to STK-001 for Dravet syndrome, highlighting its potential to improve upon current treatments by restoring NaV1.1 protein levels. • Tolebrutinib received breakthrough therapy designation for non-relapsing secondary progressive multiple sclerosis based on phase 3 trial results showing delayed disability progression. • The FDA placed a clinical hold on PepGen’s PGN-EDO51 phase 2 study for Duchenne muscular dystrophy, pending further clarification from the agency.

Sana Biotechnology's UP421 demonstrates survival and function of transplanted islet cells in a type 1 diabetes patient without immunosuppression.

• Sana Biotechnology's stock experienced a 52-week low, reflecting market challenges despite a healthy current ratio of 4.47 and analysts' price target ranging from $7 to $15. • The FDA granted Fast Track designation to Sana's SC291 for relapsed/refractory systemic lupus erythematosus, with initial clinical data from the GLEAM trial expected in 2025. • Sana is prioritizing its UP421 and SC451 programs for Type 1 diabetes and SC291 for B-cell driven autoimmune diseases, while seeking a licensing partner for deprioritized programs. • Amidst these changes, Nathan Hardy will step down as CFO in October 2024, and Dhaval Patel, M.D., Ph.D., has been appointed as the new Executive Vice President and Chief Scientific Officer.

• The FDA has granted Fast Track designation to Sana Biotechnology's SC291 for relapsed/refractory systemic lupus erythematosus (SLE). • SC291, a HIP-modified CD19-directed allogeneic CAR T therapy, is being evaluated in the GLEAM trial for B-cell mediated autoimmune diseases. • Sana Biotechnology anticipates sharing initial clinical data from the GLEAM trial in 2025, highlighting the potential of SC291. • Fast Track designation aims to expedite the development and review of drugs addressing serious conditions with unmet medical needs.